Company: GEHC
Filing Date: 2025-07-30
Form Type: 10-Q
Source: 0001932393-25-000049
Chunk: 14

Company: GE HealthCare Technologies Inc.
Filing Date: 2025-07-30
Form: 10-Q
Item: Item 1
Chunk 14
---
 operating activitiesDepreciation of property, plant, and equipment138 137 Amortization of intangible assets146 160 Gain on remeasurement of Nihon Medi-Physics equity method investment(97)— Net periodic postretirement benefit plan (income) expense(138)(180)Postretirement plan contributions(182)(170)Share-based compensation56 70 Provision for income taxes216 267 Cash paid during the year for income taxes(270)(287)Changes in operating assets and liabilities, excluding the effects of acquisitions:Receivables185 126 Inventories(188)(116)Contract and other deferred assets(48)12 Accounts payable(113)(97)Contract liabilities(23)(20)Current compensation and benefits(207)(266)All other operating activities – net(218)(161)Cash from (used for) operating activities344 300 Cash flows – investing activitiesAdditions to property, plant and equipment and internal-use software(238)(209)Purchases of businesses, net of cash acquired(279)(259)Purchases of investments(28)(30)All other investing activities – net(84)(39)Cash from (used for) investing activities(630)(537)Cash flows – financing activitiesNet increase (decrease) in borrowings (maturities of 90 days or less)1 — Newly issued debt, net of debt issuance costs (maturities longer than 90 days)1,493 1 Repayments and other reductions (maturities longer than 90 days)(261)(156)Dividends paid to stockholders(32)(28)Repurchase of common stock(100)— Proceeds from stock issued under employee benefit plans21 24 Taxes paid related to net share settlement of equity awards(33)(48)All other financing activities – net(15)(4)Cash from (used for) financing activities1,075 (210)Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash84 (41)Increase (decrease) in cash, cash equivalents, and restricted cash873 (488)Cash, cash equivalents, and restricted cash at beginning of year2,893 2,506 Cash, cash equivalents, and restricted cash at end of period$3,766 $2,018 Supplemental disclosure of cash flows informationCash paid during the year for interest$(260)$(274)Non-cash investing activities